Aberrant Toll Receptor Expression and Endotoxin Hypersensitivity in Mice Lacking a Functional TGF-β1 Signaling Pathway

Journal of Immunology

Volumn 172, Issue 6, 2004, Pages 3814-3821

  McCartney Francis, Nancy ^a   Jin, Wenwen ^a   Wahl, Sharon M ^a  

^a NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; ENDOTOXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; SMAD3 PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL CELL WALL; CACHEXIA; ENDOTOXEMIA; GENE EXPRESSION; HYPERSENSITIVITY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; INFLAMMATION; INFLAMMATORY INFILTRATE; MOUSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 1542514714     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.6.3814     Document Type: Article

References (43)

1. Kulkarni, A. B., C. G. Huh, D. Becker, A. Geiser, M. Lyght, K. C. Flanders, A. B. Roberts, M. B. Sporn, J. M. Ward, and S. Karlsson. 1993. Transforming growth factor β1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. USA 90:770.
2. McCartney-Francis, N. L., M. Frazier-Jessen, and S. M. Wahl. 1998. TGF-β: a balancing act. Int. Rev. Immunol. 16:553.
3. Lucas, P. J., S. J. Kim, S. J. Melby, and R. E. Gress. 2000. Disruption of T cell homeostasis in mice expressing a T cell-specific dominant negative transforming growth factor β II receptor. J. Exp. Med. 191:1187.
4. Gorelik, L., and R. A. Flavell. 2000. Abrogation of TGFβ signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 12:171.
5. Hahm, K. B., Y. H. Im, T. W. Parks, S. H. Park, S. Markowitz, H. Y. Jung, J. Green, and S. J. Kim. 2001. Loss of transforming growth factor β signalling in the intestine contributes to tissue injury in inflammatory bowel disease. Gut 49:190.
6. Yang, X., J. J. Letterio, R. J. Lechleider, L. Chen, R. Hayman, H. Gu, A. B. Roberts, and C. Deng. 1999. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-β. EMBO J. 18:1280.
7. Vodovotz, Y., A. G. Geiser, L. Chesler, J. J. Letterio, A. Campbell, M. S. Lucia, M. B. Sporn, and A. B. Roberts. 1996. Spontaneously increased production of nitric oxide and aberrant expression of the inducible nitric oxide synthase in vivo in the transforming growth factor β1 null mouse. J. Exp. Med. 183:2337.
8. McCartney-Francis, N. L., and S. M. Wahl. 2002. Dysregulation of IFN-γ signaling pathways in the absence of TGF-β1. J. Immunol. 169:5941.
9. Li, Q., and I. M. Verma. 2002. NF-κB regulation in the immune system. Nat. Rev. Immunol. 2:725.
10. May, M. J., and S. Ghosh. 1998. Signal transduction through NF-κB. Immunol. Today 19:80.
11. Zhang, G., and S. Ghosh. 2001. Toll-like receptor-mediated NF-κB activation: a phylogenetically conserved paradigm in innate immunity. J. Clin. Invest. 107:13.
12. Jobin, C., and R. B. Sartor. 2000. The IκB/NF-κB system: a key determinant of mucosal inflammation and protection. Am. J. Physiol. 278:C451.
13. Handel, M. L., L. B. McMorrow, and E. M. Gravallese. 1995. Nuclear factor-κB in rheumatoid synovium: localization of p50 and p65. Arthritis Rheum. 38:1762.
14. Marok, R., P. G. Winyard, A. Coumbe, M. L. Kus, K. Gaffney, S. Blades, P I. Mapp, C. J. Morris, D. R. Blake, C. Kaltschmidt, and P. A. Baeuerle. 1996. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum. 39:583.
15. Medzhitov, R., and C. Janeway, Jr. 2000. The Toll receptor family and microbial recognition. Trends Microbiol. 8:452.
16. Means T. K., D. T. Golenbock, and M. J. Fenton. 2000. The biology of Toll-like receptors. Cytokine Growth Factor Rev. 11:219.
17. Medzhitov, R., P. Preston-Hurlburt, and C. A. Janeway, Jr. 1997. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394.
18. Poltorak, A., X. He, I. Smirnova, M. Y. Liu, C. Van Huffel, X. Du, D. Birdwell, E. Alejos, M. Silva, C. Galanos, et al. 1998. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 282:2085.
19. Qureshi, S. T., L. Lariviere, G. Leveque, S. Clermont, K. J. Moore, P. Gros, and D. Malo. 1999. Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (Tlr4). J. Exp. Med. 189:615.
20. Takeuchi, O., K. Hoshino, T. Kawai, H. Sanjo, H. Takada, T. Ogawa, K. Takeda, and S. Akira. 1999. Differential roles of TLR2 and TLR4 in recognition of Gram-negative and Gram-positive bacterial cell wall components. Immunity 11:443.
21. McCartney-Francis, N. L., D. E. Mizel, R. S. Redman, M. Frazier-Jessen, R. B. Panek, A. B. Kulkarni, J. M. Ward, J. B. McCarthy, and S. M. Wahl. 1996. Autoimmune Sjogren's-like lesions in salivary glands of TGF-β1-deficient mice are inhibited by adhesion-blocking peptides. J. Immunol. 157:1306.
22. Palombella, V. J., E. M. Conner, J. W. Fuseler, A. Destree, J. M. Davis, F. S. Laroux, R. E. Wolf, J. Huang, S. Brand, P. J. Elliott, et al. 1998. Role of the proteasome and NF-κB in streptococcal cell wall-induced polyarthritis. Proc. Natl. Acad. Sci. USA 95:15671.
23. Dewan, M. Z., K. Terashima, M. Taruishi, H. Hasegawa, M. Ito, Y. Tanaka, N. Mori, T. Sata, Y. Koyanagi, M. Maeda, et al. 2003. Rapid tumor formation of human T-cell leukemia virus type 1-infected cell lines in novel NOD-SCID/ γc(null) mice: suppression by an inhibitor against NF-κB. J. Virol. 77:5286.
24. Salkowski, C. A., K. E. Thomas, M. J. Cody, and S. N. Vogel. 2000. Impaired IFN-γ production in IFN regulatory factor-1 knockout mice during endotoxemia is secondary to a loss of both IL-12 and IL-12 receptor expression. J. Immunol. 165:3970.
25. McCartney-Francis, N. L., D. E. Mizel, M. Frazier-Jessen, A. B. Kulkarni, J. B. McCarthy, and S. M. Wahl. 1997. Lacrimal gland inflammation is responsible for ocular pathology in TGF-β1 null mice. Am. J. Pathol. 151:1281.
26. Grisham, M. B., V. J. Palombella, P. J. Elliott, E. M. Conner, S. Brand, H. L. Wong, C. Pien, L. M. Mazzola, A. Destree, L. Parent, and J. Adams. 1999. Inhibition of NF-κB activation in vitro and in vivo: role of 26S proteasome. Methods Enzymol. 300:345.
27. Qureshi, N., P. Y. Perera, J. Shen, G. Zhang, A. Lenschat, G. Splitter, D. C. Morrison, and S. N. Vogel. 2003. The proteasome as a lipopolysaccharide-binding protein in macrophages: differential effects of proteasome inhibition on lipopolysaccharide-induced signaling events. J. Immunol. 171:1515.
28. Dobrovolskaia, M. A., and S. N. Vogel. 2002. Toll receptors, CD14, and macrophage activation and deactivation by LPS. Microbes Infect. 4:903.
29. Van Amersfoort, E. S., T. J. Van Berkel, and J. Kuiper. 2003. Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock. Clin. Microbiol. Rev. 16:379.
30. Hines, K. L., A. B. Kulkarni, J. B. McCarthy, H. Tian, J. M. Ward, M. Christ, N. L. McCartney-Francis, L. T. Furcht, S. Karlsson, and S. M. Wahl. 1994. Synthetic fibronectin peptides interrupt inflammatory cell infiltration in transforming growth factor β1 knockout mice. Proc. Natl. Acad. Sci. USA 91:5187.
31. Diebold, R. J., M. J. Eis, M. Yin, I. Ormsby, G. P. Boivin, B. J. Darrow, J. E. Saffitz, and T. Doétschman. 1995. Early-onset multifocal inflammation in the transforming growth factor β1-null mouse is lymphocyte mediated. Proc. Natl. Acad. Sci. USA 92:12215.
32. Letterio, J. J., A. G. Geiser, A. B. Kulkarni, H. Dang, L. Kong, T. Nakabayashi, C. L. Mackall, R. E. Gress, and A. B. Roberts. 1996. Autoimmunity associated with TGF-β1-deficiency in mice is dependent on MHC class II antigen expression. J. Clin. Invest. 98:2109.
33. Lorenz, E., J. P. Mira, K. L. Frees, and D. A. Schwartz. 2002. Relevance of mutations in the TLR4 receptor in patients with Gram-negative septic shock. Arch. Intern. Med. 162:1028.
34. Aliprantis, A. O., R. B. Yang, M. R. Mark, S. Suggett, B. Devaux, J. D. Radolf, G. R. Klimpel, P. Godowski, and A. Zychlinsky. 1999. Cell activation and apoptosis by bacterial lipoproteins through Toll-like receptor-2. Science 285:736.
35. Hou, L., H. Sasaki, and P. Stashenko. 2000. Toll-like receptor 4-deficient mice have reduced bone destruction, following mixed anaerobic infection. Infect. Immun. 68:4681.
36. Chen, W., and S. M. Wahl. 2002. TGF-β: receptors, signaling pathways and autoimmunity. Curr. Dir. Autoimmun. 5:62.
37. Boivin, G. P., I. Ormsby, J. Jones-Carson, B. A. O'Toole, and T. Doetschman. 1997. Germ-free and barrier-raised TGFβ1-deficient mice have similar inflammatory lesions. Transgenic Res. 6:197.
38. Hausmann, M., S. Kiessling, S. Mestermann, G. Webb, T. Spottl, T. Andus, J. Scholmerich, H. Herfarth, K. Ray, W. Falk, and G. Rogler. 2002. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 122:1987.
39. Fiocchi, C. 2001. TGF-β/Smad signaling defects in inflammatory bowel disease: mechanisms and possible novel therapies for chronic inflammation. J. Clin. Invest. 108:523.
40. Monteleone, G., A. Kumberova, N. M. Croft, C. McKenzie, H. W. Steer, and T. T. MacDonald. 2001. Blocking Smad7 restores TGF-β1 signaling in chronic inflammatory bowel disease. J. Clin. Invest. 108:601.
41. Arbour, N. C., E. Lorenz, B. C. Schutte, J. Zabner, J. N. Kline, M. Jones, K. Frees, J. L. Watt, and D. A. Schwartz. 2000. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat. Genet. 25:187.
42. Kiechl, S., E. Lorenz, M. Reindl, C. J. Wiedermann, F. Oberhollenzer, E. Bonora, J. Willeit, and D. A. Schwartz. 2002. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347:185.
43. Zuany-Amorim, C., J. Hastewell, and C. Walker. 2002. Toll-like receptors as potential therapeutic targets for multiple diseases. Nat. Rev. Drug Discov. 1:797.